Published in Biotech Business Week, July 12th, 2004
The 4-year, 15,245-patient trial compared the calcium channel blocker Norvasc with the angiotensin-receptor blocker valsartan. Norvasc patients reached lower blood pressure levels earlier, and maintained better blood pressure control throughout the trial compared with valsartan patients. In addition, Norvasc patients were treated with fewer add-on medications than valsartan...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.